Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Development of Blood Vessels01:07

Development of Blood Vessels

The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways.

Nature communications·2025
Same author

Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade.

Cell reports. Medicine·2025
Same author

Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis.

Cancer research·2025
Same author

Adenosine diphosphate stimulates VEGF-independent choroidal endothelial cell proliferation: A potential escape from anti-VEGF therapy.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Metronomic chemotherapy and drug repurposing: Two sides of an oncology coin to reduce host and financial toxicity.

Cancer letters·2025

Video Experimental Relacionado

Updated: Jun 25, 2026

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber
09:55

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber

Published on: May 30, 2016

La angiogénesis como objetivo terapéutico.

Napoleone Ferrara1, Robert S Kerbel

  • 1Genentech, 1 DNA Way, South San Francisco, California 94080, USA. nf@gene.com

Nature
|December 16, 2005
PubMed
Resumen

La inhibición de la angiogénesis ofrece un tratamiento prometedor para el cáncer y la degeneración macular relacionada con la edad. Una mayor comprensión de la morfogénesis vascular es crucial para el avance de la angiogénesis terapéutica en la medicina cardiovascular.

Área de la Ciencia:

  • Ciencias biomédicas Ciencias biomédicas.
  • Medicina cardiovascular La medicina cardiovascular es una especialidad de la medicina cardiovascular.
  • Oncología Oncología.

Sus antecedentes:

  • La angiogénesis, la formación de nuevos vasos sanguíneos, es un proceso crítico tanto en condiciones fisiológicas como patológicas.
  • La inhibición de la angiogénesis es una estrategia terapéutica validada para los cánceres y la degeneración macular relacionada con la edad.
  • La angiogénesis terapéutica tiene como objetivo promover el crecimiento de los vasos sanguíneos para el tratamiento de trastornos isquémicos.

Objetivo del estudio:

  • Para resumir el progreso en las terapias anti-angiogénicas.
  • Para resaltar el potencial de la angiogénesis terapéutica.
  • Identificar la necesidad de una mayor investigación sobre la morfogénesis vascular.

Más Videos Relacionados

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

Simple and Effective Procedure for Hemostasis in Mouse Arteries
05:34

Simple and Effective Procedure for Hemostasis in Mouse Arteries

Published on: November 28, 2025

Videos de Experimentos Relacionados

Last Updated: Jun 25, 2026

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber
09:55

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber

Published on: May 30, 2016

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

Simple and Effective Procedure for Hemostasis in Mouse Arteries
05:34

Simple and Effective Procedure for Hemostasis in Mouse Arteries

Published on: November 28, 2025

Principales métodos:

  • Revisión de los avances recientes en el desarrollo de fármacos antiangiogénicos.
  • Análisis de los agentes antiangiogénicos aprobados.
  • Discusión de los mecanismos subyacentes a la morfogénesis vascular.

Principales resultados:

  • Se han logrado avances significativos en el desarrollo de tratamientos antiangiogénicos.
  • Varios agentes antiangiogénicos han recibido aprobación regulatoria.
  • Comprender la morfogénesis vascular es clave para desarrollar nuevas terapias.

Conclusiones:

  • La inhibición de la angiogénesis es una estrategia exitosa para el tratamiento de enfermedades específicas.
  • La angiogénesis terapéutica presenta un futuro prometedor para la medicina cardiovascular.
  • La investigación continua sobre los mecanismos fundamentales de la formación de los vasos sanguíneos es esencial.